PRECISION ONCOLOGY & INFLAMMATION THERAPEUTICS
Advancing the next generation of precision oncology and inflammation therapeutics.
At Allterum Therapeutics, we are pioneering breakthrough medicines shaped by rigorous science, deep clinical insight, and an unwavering commitment to the patients who motivate everything we do.
Mission
We advance precision medicine
through uncompromising science and meaningful innovation—developing oncology and inflammation therapies that deliver extraordinary accuracy, transform treatment pathways, and change patient lives…because #PatientsCantWait.
Vision
We aim to set a new standard for
precision therapeutics. Our vision is to build
a world-class organization at the forefront of oncology and inflammation—accelerating discovery, elevating patient care, and expanding what's possible for people everywhere.
ABOUT US
Curiosity fuels us. Courage moves us forward.
Purpose keeps us focused.
A Brief History of 4A10
Developing Treatments for CD127 Expressing Cancers
With an initial focus on hematological malignancies, Allterum Therapeutics is developing 4A10, an anti-CD127 monoclonal antibody for treating acute lymphoblastic leukemia (ALL), B-cell malignancies, and lymphomas with CD127 expression. Allterum is also exploring relapsed/refractory solid tumors with CD127 expression. The 4A10 antibody was developed at the National Cancer Institute (NCI) and licensed exclusively to Fannin.
Allterum is a Fannin portfolio company. It is an early-stage life science commercialization group, which has assigned its executed license. The company is working with national leaders in cancer at Baylor College of Medicine, Texas Children’s Hospital, the NCI, the Leukemia and Lymphoma Society, and The University of Texas MD Anderson Cancer Center to develop the technology.
Continuing the Fight in Hematologic Malignancies
At Allterum, we are dedicated to advancing innovative, targeted therapies for patients facing the greatest unmet needs in oncology.While survival rates for acute lymphoblastic leukemia (ALL) have improved significantly, individuals with relapsed or refractory T-cell ALL and certain B-cell hematologic malignancies still have limited treatment options. Our mission is to develop precise, effective therapies that improve outcomes and offer new hope to the patients who need it most.
Exploring Other CD127 Expressing Cancers
Ongoing pre-clinical studies focused on lymphomas and solid tumors will extend Allterum’s clinical program to other metastatic disease with CD127 expression where the overall survival is limited given current approved therapies.
Clinical Trial Sites
OUR TEAM
Our people are the engine behind every breakthrough.
The Allterum team brings together expertise in drug development, biology, chemistry, and translational science, enhanced by Houston’s dynamic bio-innovation ecosystem. Through collaboration and a culture of curiosity and ambition, we are advancing the potential of precision medicine.
Chief Executive Officer
Dr. Yan Moore is a physician leader with 26 years of experience across oncology, immunology, rare disease, translational medicine, and global product development. He has led corporate strategy, portfolio prioritization, cross-functional organizations, and clinical, regulatory, partnership, and commercialization efforts, translating platform science into enterprise value and patient impact. Prior to Allterum, Dr. Moore served as CMO of Omega Therapeutics and SVP, Global Head of Oncology at Ipsen, with prior roles at Sanofi, GSK, BMS, and emerging biotechs. He holds BSc and MD degrees from Tel Aviv University’s Sackler School of Medicine, an MBA from Drexel University, and completed executive programs at Harvard Business School and London Business School.
President, Research & Development
Atul Varadhachary, MD, Ph.D., serves as a member of the Board of Directors and President R&D for Allterum Therapeutics. He served as CEO for Allterum from July 2018 to December 2024. In addition to his role at Allterum, Atul has served as the Managing Partner at Fannin since 2013. Dr. Varadhachary is an experienced biotech entrepreneur who has helped lead over a dozen development programs in oncology, including seven in clinic with one progressing to Phase 3 clinical trial.
Chief Medical Officer
Philip Breitfeld, MD is a pharmaceutical industry executive focusing on strategic drug development in oncology. He is a Pediatric Hematologist-Oncologist with a 20 year academic career spanning basic cell and molecular biology to clinical investigation. In his more than 20 years in the pharmaceutical industry, Dr. Breitfeld has leadership positions in biotech, traditional pharma, and contract research organizations.
Head of Clinical Operations
Head of Clinical Operations. Dr. Schaumberg has more than 30 years of drug development expertise, including experience with global pharmaceutical organizations, biotechnology companies and clinical research organizations. His past roles include Vice President level positions in Biotech as Senior Vice President, Clinical Operations of Agennix AG as well as Vice President level positions in the clinical research organizations PRA International and Inveresk. Jack also serves as Head of Clinical Operations for Pulmotect, Inc.
OUR SCIENCE
Pioneering Precision Medicine
4A10 is designed to target CD127, a central mediator of IL-7 signaling implicated in cancer cell survival and treatment resistance, representing a promising immune-directed therapeutic opportunity in CD127+ malignancies.
Targeting CD127 Biology
4A10 targets CD127, a central driver of IL-7 signaling in cancer biology.
By doing this, it is designed to block a biologically important pathway driving tumor survival and resistance.
Differentiated Mechanism
4A10 combines three mechanisms—blocking signaling, inducing ADCC, and promoting ADCP.
It is the only CD127-targeted therapy in development with ADCC capability, enhancing immune-mediated killing.
Strong Preclinical Efficacy & Safety
4A10 has demonstrated potent antitumor activity across ALL models, including chemo-resistant settings and in combination with chemotherapy. Activity also extends to other CD127-positive cancers such as AML and lymphoma. Preclinical studies showed a favorable safety and tolerability profile, with no dose-limiting toxicities observed.
Targeted Clinical Development
Clinical development is focused on relapsed/refractory ALL and lymphoblastic lymphoma, where unmet need remains high.
Allterum’s future plans include expansion into additional non-ALL hematologic malignancies and solid tumors.
PIPELINE
Our Therapeutic Pipeline
A diversified portfolio targeting high-unmet-need indications in oncology and inflammation.
Lead Program
(AML, Lymphomas, Others)
(Lung, Colorectal, Breast, Others)
Early Development Pipeline Programs
[Undisclosed Joint Development]
Autoimmune Disorders
[Undisclosed Joint Development]
Key Science Collaborators
Working alongside world-class institutions to accelerate the development of transformative therapies.
“ I am excited to work with Allterum to develop a much-needed option for the treatment of children with T-cell ALL.”
Eric Schafer
Study Chair, M.D., M.H.S. Assist. Professor, Pediatrics-Oncology | Texas Children's Hospital & Baylor College of Medicine
”After years of searching for a way to help those kids who have no effective treatment for their leukemia, I’m thrilled to see Allterum take our antibody into the clinic.”
Scott Durum
Ph.D. Section Chief and Antibody discoverer | Cytokine and Immunity Section | National Cancer Institute
Industry Partners
Fujifilm Diosynth
Biotechnologies
Global Operations
Cancer Prevention & Research
Institute of Texas
Austin, Texas
Fannin
Innovation Studio
Houston, Texas
Worldwide Clinical Trials
Houston, Texas
LabCorp
Houston, Texas
Pharmaron
Catalent
Navitas Clinical Research
Latest Updates
Immunology Drug Developer Veteran Brian Wipke, Ph.D., Joins Fannin and Allterum Therapeutics
Read MoreAdvancing Hope for Children with Leukemia: Allterum Therapeutics Receives FDA Fast Track Designation for 4A10 in Acute Lymphoblastic Leukemia
Read MoreHope in Fight Against Pediatric Cancers: Allterum Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Appl. for 4A10 in Acute Lymphoblastic Leukemia
Read MoreAllterum Therapeutics Awarded $1 Million SBIR Grant from NCI to Support Clinical Development of 4A10 in Childhood Leukemia
Read MoreJoin Our Team
Clinical Operations Manager
Lead and oversee day-to-day clinical trial operations across Allterum's oncology pipeline. This role involves site activation, vendor management, and ensuring study timelines and quality standards are consistently met.
- Manage clinical site relationships and site activation timelines
- Oversee CRO and vendor performance across Phase 1–3 studies
- Drive inspection-readiness and SOPs compliance
- Cross-functional collaboration with clinical development, regulatory, and data management teams
Clinical Trial Manager
Responsible for the end-to-end management and execution of clinical trials within Allterum's hematology and oncology programs. This role ensures high-quality study delivery, operational excellence, and regulatory compliance.
- Lead trial execution from protocol development through database lock
- Manage investigative site monitoring and data quality oversight
- Coordinate cross-functional teams including medical, regulatory, and biostatistics
- Maintain TMF integrity and ensure GCP compliance throughout study lifecycle
Commitment to Patient Access
Expanded Access Policy for 4A10
Allterum Therapeutics is developing 4A10 as an investigational therapy for patients with T-cell Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma. At this stage of development, 4A10 is available only through participation in clinical trials. Because clinical development is ongoing and supply is limited, Allterum Therapeutics is not offering Expanded Access (compassionate use) to 4A10 outside of clinical trials at this time.
We will review this policy periodically as additional safety, efficacy, and manufacturing data become available. Any updates will be posted on this page.
For information about active or upcoming clinical studies, please refer to:
ALT-101